Skip to content
Clinical Trials – home
Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
Sponsor

Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Spain Avinguda De La Gran Via De L'hospitalet 199, 08908 L'hospitalet De Llobregat, Spain

About the sponsor

Solid tumours are a major focus, including advanced solid tumours, germ cell tumours, metastatic uveal melanoma, and cutaneous squamous cell carcinoma. The portfolio also includes studies in tumour immune resistance and anti-PD-1 therapy.

  • Advanced solid tumours
  • Germ cell tumours
  • Metastatic uveal melanoma
  • Cutaneous squamous cell carcinoma

Research activity in this area includes cell-based immunotherapy, tumour response assessment, and the study of biomarkers linked to treatment resistance.

About Specializations

Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL runs clinical trials in conditions such as Renal transplant, Diabetes prophylaxis, Insomnia, Major depression, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

14 clinical trials

Insomnia+1

Recruiting

Daridorexant for Insomnia in Patients with Major Depressive Disorder and Moderate to Severe Insomnia

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daridorexant
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Pyelonephritis

Recruiting

Comparing the effectiveness of 7 days versus 14 days of ciprofloxacin or ceftriaxone for treating kidney infection in kidney transplant recipients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ceftriaxone
  • Sponsor:Bellvitge University Hospital

Study of Autologous Tumor-Infiltrating Lymphocytes with Cyclophosphamide, Fludarabine and Aldesleukin in Patients with Germ Cell Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Study on Efgartigimod for Early Treatment in Patients with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Bellvitge University Hospital

Study on Reducing HPV Infectivity in HPV-Positive Women Using 9vHPV Vaccine

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
  • Sponsor:Bellvitge University Hospital

A study of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Uveal melanoma

Not recruiting

Study of AloCelyvir for Patients with Metastatic Uveal Melanoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogenic Bone Marrow-Derived Mesenchymal Stem Cells Transduced With Icovir-5, Ex Vivo Expanded
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Study on the Effects of Loratadine and Rapamycin for Patients with Lymphangioleiomyomatosis (LAM)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Loratadine
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Adrenoleukodystrophy

Not recruiting

Study on the Effects of Dimethyl Fumarate for Patients with Adrenomyeloneuropathy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Dimethyl Fumarate
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Niemann-Pick disease

Not recruiting

Study on the Safety and Long-Term Effects of Efavirenz for Adults and Late-Onset Juvenile Niemann-Pick Type C Disease with Cognitive Impairment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Aprepitant
  • Sponsor:Bellvitge University Hospital

Neoplasm malignant

Not recruiting

Study on the Effectiveness of Autologous Tumor-Infiltrating Lymphocytes, Aldesleukin, Fludarabine Phosphate, and Cyclophosphamide in Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

End stage renal disease+1

Not recruiting

Study Comparing Rifampicin, Isoniazid, and Rifapentine Regimens for Treating Latent Tuberculosis in Patients with End-Stage Kidney Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Isoniazid
  • Sponsor:Bellvitge University Hospital

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.